Copy
Genix Pharmaceuticals Appoints Raylen Tamayo as CFO
Vancouver, British Columbia — May 5, 2026 — Leads & Copy — Genix Pharmaceuticals Corporation (TSX-V: GENX) has announced the resignation of Mr. Danny Lee as Chief Financial Officer, effective April 30, 2026. Lee is leaving the role to focus on other business obligations.
The company has appointed Ms. Raylen Tamayo as the new Chief Financial Officer, effective May 4, 2026. Tamayo brings over eight years of experience in finance and accounting, primarily within publicly listed companies.
The Genix team thanked Lee for his contributions to the company since December 2020 and wished him success in his future endeavors.
Tamayo's career began as an assurance and consulting associate at a top accounting firm. She has since advanced through senior finance roles across a range of sectors. Her expertise includes IFRS compliance, financial reporting and management, control and process streamlining, as well as advisory services for initial public offerings (IPOs) and reverse takeovers (RTOs).
Tamayo currently serves as a Manager at Zeus Accounting Solutions Corp., where she also holds Controller roles for several companies. She holds a Master’s degree from the University Canada West, where she majored in Finance.
Genix Pharmaceuticals Corporation is a Canadian ophthalmic drugs company. The company focuses on the research, development, manufacture, licensing, and sales of novel prescription and OTC ophthalmological products. These products are designed to meet the growing needs of consumers worldwide, especially aging baby boomers. The company has several products awaiting Health Canada approval.
Mr. Mahmoud S. Aziz, President and Director, made the announcement on behalf of the Board of Directors.